<DOC>
	<DOCNO>NCT00002461</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill cancer cell . PURPOSE : This phase II trial study give high-dose chemotherapy follow bone marrow peripheral stem cell transplantation see well work treat patient refractory Hodgkin 's disease non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Refractory Hodgkin 's Disease Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity intensive carmustine etoposide cisplatin cyclophosphamide , follow rescue autologous bone marrow ( ABM ) treat vitro etoposide and/or peripheral blood stem cell mobilize filgrastim ( G-CSF ) sargramostim ( GM-CSF ) without radiotherapy patient refractory Hodgkin 's disease non-Hodgkin 's lymphoma . II . Determine time recovery peripheral blood count patient treat regimen . III . Correlate rate peripheral blood cell recovery patient vitro growth ABM treat etoposide . OUTLINE : This multicenter study . Autologous bone marrow ( ABM ) harvest two-thirds ABM treat vitro etoposide ( VP-16 ) . ABM may store early course disease patient high risk relapse previously treat agent cause bone marrow stem cell damage ( e.g. , nitrosoureas , pelvic irradiation ) . Patients prior bone marrow involvement subsequent bone marrow remission must receive 1 2 additional course chemotherapy undergo harvest ABM . Patients PBSC rescue alone plan also undergo ABM harvest case back-up ABM rescue need . Patients receive sargramostim ( GM-CSF ) filgrastim ( G-CSF ) subcutaneously begin 5 day harvest peripheral blood stem cell ( PBSC ) continue completion harvest . Patients without extensive prior radiotherapy undergo radiotherapy area measurable active disease plus 2 cm margin day -21 -17 -14 -8 . Patients without contraindication cisplatin ( e.g. , hear impairment , peripheral neuropathy ) receive cisplatin IV 3 hour day -7 -3 carmustine IV 2 hour VP-16 IV 4 hour day -6 -4 . Patients contraindication cisplatin receive cyclophosphamide IV every 12 hour , VP-16 IV 1 hour every 12 hour , carmustine IV 1 hour day -7 -4 . ABM and/or PBSC reinfused day 0 . The first 6 ABM rescue patient receive untreated ABM subsequent patient receive ABM treat vitro VP-16 . Patients bone marrow biopsy show evidence regeneration ( marrow cellularity le 1 % ) day 21 PBSC rescue undergo back-up ABM rescue . Patients without engraftment ( granulocyte count le 500/mm3 untransfused platelet great 20,000/mm3 ) day 28 rescue ABM treat vitro VP-16 undergo rescue untreated ABM . PROJECTED ACCRUAL : A total 21-46 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis resistant Hodgkin 's disease Eligible subtypes : Lymphocytic predominance Nodular sclerosing Mixed cellularity Lymphocyte deplete Not otherwise specify Must meet 1 follow condition : Disease progression least 1 course prior therapy 2 regimen comprise combination chemotherapy radiotherapy Less partial remission ( PR ) least 2 course 2 regimen Failure achieve complete remission ( CR ) 6 course 1 2 regimen Relapse le 1 year initial therapy OR Diagnosis intermediate highgrade nonHodgkin 's lymphoma ( NHL ) Eligible subtypes : Diffuse poorly differentiate lymphocytic Diffuse mixed lymphocytichistiocytic Nodular histiocytic Diffuse histiocytic Diffuse undifferentiated Lymphoblastic Must meet 1 follow condition : Disease progression 1 course prior therapy Failure achieve PR 2 course prior therapy Failure achieve CR 6 course prior therapy OR Diagnosis lowgrade NHL Eligible subtypes : Diffuse welldifferentiated lymphocytic Nodular poorly differentiate lymphocytic Nodular mix lymphocytichistiocytic Failure secondline therapy administer progressive symptomatic disease organ compromise Measurable disease physical exam , external imaging scan study , tumor marker No severe symptomatic CNS disease etiology History prior CNS tumor allow sign symptom study entry Active CNS lymphoma ( meningeal lymphomatosis ) render diseasefree conventional therapy allow Epidural metastasis discrete parenchymal brain lesion allow tumor encompass standard treatment field Bilateral marrow core biopsy free tumor show least 30 % cellularity Prior marrow involvement allow marrow histologically normal time storage No significant skin breakdown due tumor disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Karnofsky 70100 % OR ECOG 01 Life expectancy : At least 8 week without transplantation Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 1.8 mg/dL SGOT SGPT less 2 time normal No high risk venoocclusive disease liver Renal : No severe renal dysfunction unless due tumor invasion Creatinine 1.5 mg/dL Creatinine least 60 mL/min Cardiovascular : No severe cardiovascular dysfunction unless due tumor invasion No myocardial infarction within past 6 month No symptom major heart disease Ejection fraction least 50 % MUGA scan Essential hypertension control medication allow Pulmonary : No severe pulmonary dysfunction unless due tumor invasion DLCO least 50 % normal No symptomatic obstructive restrictive pulmonary disease Other : No insulindependent diabetes mellitus No uncompensated major thyroid adrenal dysfunction No active infection HTLVIII negative ( AIDSrelated complex ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( least 6 week since prior nitrosoureas mitomycin ) Prior exposure etoposide , cisplatin , carmustine allow cumulative dose chloroethylnitrosourea ( carmustine lomustine ) great 400 mg/m2 Prior doxorubicin daunorubicin dose 450 mg/m2 allow LVEF least 50 % No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid hypercalcemia allow Radiotherapy : See Disease Characteristics No prior wholepelvic radiotherapy Other prior radiotherapy allow Surgery : Not specify Other : No concurrent nitroglycerin preparation angina pectoris No concurrent antiarrhythmic drug major ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>